@sameem_abedin profile picture
Sameem Abedin @sameem_abedin

Leukemia/BMT Doc, dad, steeler fan(atic)

Joined November 2018
  • Tweets 116
  • Following 85
  • Followers 133
10 Photos and videos
Sameem Abedin retweeted
Froedtert
@Froedtert
10 May 2023
We are proud of staff like Darryl Taylor, who works at Froedtert Hospital in Environmental Services. Darryl went the extra mile in his workday, offering support and friendship to patient Lindsey Jacob and her family. tmj4.com/news/local-news/can…

Cancer Connection: Hospital housekeeper who lost wife, builds special bond with cancer patient and...

Despite what he has gone through in his own life, Darryl has been a blessing to others through their darkest times.

tmj4.com
1
2
9
935
Sameem Abedin retweeted
Cam Harless
@camharless
1 Mar 2023
every american president, but they're all cool and they all sport a mullet 46. Joe Biden
2,279
15,832
105,600
19,623,358
This good boy is 9 years old today
12
560
Sameem Abedin retweeted
Mehdi Hamadani, MD@MediHumdani
10 Feb 2023
We at @MedicalCollege are looking for energetic faculty looking to build a career in HCT & CART therapy with a focus on myeloid &/or plasma cell disorder. Home of @CIBMTR / @BMTCTN - No🌪️ - No - No 🔥 - No 🌀 Chilly yes but warm Friendly people. DM or meet at Tandem #bmtsm
2
12
44
7,438
A morning of clay sculpting/painting to answer the ultimate what if… what if instead of an iceberg, a bloop actually ate the Titanic?
3
210
Sameem Abedin retweeted
FIFA World Cup
@FIFAWorldCup
18 Dec 2022
MESSI SCORES FOR ARGENTINA!!
1,088
16,310
122,710
6,245,028
Whoa
1
133
In leukemias, are there any studies demonstrating benefit to post-HCT maintenance therapy in patients who enter transplant in an MRD negative state? Thanks @MediHumdani @sghmd @DrChrisHourigan
1
202
#ASH22. After single induction (7 3), for residual disease, lower intensity re-induction (Ven/HMA) was feasible and comparable to another cycle of 7 3, leading to less time in the hospital, NF and transfusions. MCW experience, but now a widespread practice.
1
3
17
Have a pt with Int Risk AML, got 7 3 and D 15&20 marrow 13% blasts. Discussed MA HCT, put him on a low intensity trtmt (HMA/Ven), said we’ll do HCT ASAP. This was 3 wks ago, have a Peer to Peer on Friday to seek HLA typing relatives…
1
#ASH22 thanks for the soccer coverage this weekend, but where can I watch FOOTBALL today?
Pittsburgh Steelers
@steelers
11 Dec 2022
1️⃣4️⃣
0:12
1
Sameem Abedin retweeted
AML Hub
@AML_Hub
10 Dec 2022
CONGRESS | #ASH22 Sameem Abedin @sameem_abedin, @MedicalCollege shows 53% 1 year OS and 32% at 2 years with salvage lintuzumab-Ac225 (actimab-A) plus CLAG-M in phase 1 trial in patients with R/R AML, with 64% progressing to allo-HSCT. #leusm #medicalcongress
6
7
Wow, Go Blue!
1
1
Responses: 52% achieved a CRc. At our RP2D, 67% achieved CRc. CRc patients mostly (72%) were MRD negative by MFC. Most patients had at least 1 year of follow up, and we observed a median OS of 1 year, and estimated 2-year survival of 32%. 9/
1
1
In summary - safe to give LintuzumabAc225 at low doses with intensive chemo. Counts come back. Given study population, LintuzumabAc225 appears to add in eliminating disease; would not have expected as high or as long of a response with salvage in this population.
2
13/15 responders had an ANC>1000, median 34 days, 7/15 responders had platelets >50k, median 39 days. A couple had platelets recovering, not to 50k, but moved onto HCT. Overall, acceptable, I think. 8/
1
1
Therefore, we ended up treating a majority Ven exposed patients (55%), and these patients had Ven-resistant disease - mostly adverse risk disease (67%), overall, 52% had mutations in TP53. A "trial" patient population definitely, not a typical "salvage chemo" population. 6/
1
1
Safety results: I was mostly interested excessive cytopenias from adding a cytopenia producing agent to intensive salvage chemotherapy. Higher dose LintuzumabAc225 monotherapy did not have other toxicities of note other than transient transaminitis. 7/
1
1
We therefore proposed a study to administer our SOC salvage regimen, CLAG-M, given at standard dosing, with escalating doses of LintuzumabAc225. Patients received LintuzumabAc225 delivering radioactivity ranging from 0.25 microcurie to 1.0 microcurie as a single dose. 4/
1
Patients Enrolled: To me, this was the most interesting part. This study occurred in the post-Venetoclax era. Reviewing patients chronologically, 2019 on, patients with bad disease got Ven/HMA even if fit, relapses got Ven/HMA, even while label is for ND-AML. 5/
1
Excited to present results of our investigator-initiated trial, which administered LintuzumabAc225 after CLAG-M salvage for RR-AML at #ASH22. At a moderate volume center, it was a labor of love, taking 4 years to fully enroll, but worth it due to some noteworthy responses. 1/
3
4
18
more replies
With trials few and far between that yield disease clearance, we brainstormed how this active drug may be better delivered. We hypothesized if chemo first could clear some disease, then lower doses of Lintuzumab-Ac225 may be adequate to clear residual disease, more safely. 3/
1
Load more